G-7322 GW590735, Free Acid, >99%

Prices_reduced
  • Size
  • US $
  • €
  • £
  • ¥
  • 5 mg
  • 56
  • 51
  • 44
  • 8,100
  • Add to Cart Qty:
  • In stock
  • 10 mg
  • 78
  • 72
  • 62
  • 11,300
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 148
  • 137
  • 117
  • 21,400
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 248
  • 230
  • 197
  • 35,900
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 366
  • 339
  • 291
  • 53,000
  • Add to Cart Qty:
  • In stock
  • 300 mg
  • 855
  • 793
  • 681
  • 123,900
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 1,170
  • 1,085
  • 932
  • 169,500
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 32 Other Countries
  • M.W. 478.48
  • C23H21F3N2O4S
  • [622402-22-6]

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • GW590735 is a potent and selective PPARalpha agonist. It stimulated PPARalpha with an EC50 of 4 nM and had at least 500-fold selectivity on PPARalpha versus PPARdelta and PPARgamma. It raised circulating levels of high-density lipoprotein cholesterol.  Sierra M.L., et al. "Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonist. 1. Discovery of a novel series of potent HDLc raising agents." J. Med. Chem. 50(4): 685-695 (2007).
  • GW590735 potently increased high-density lipoprotein (HDL) cholesterol, decreased low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) cholesterol, and significantly lowered triglycerides in human ApoB100/human CETP transgenic mice. Hansen M.K., et al. "Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice." J. Cardiovasc. Pharmacol. Ther. 15(2): 196-202 (2010).
  • Circulating FGF21 significantly increased in response to treatment with PPAR alpha (39%) and PPAR delta (32%), but not PPAR gamma agonist in humans.  Christodoulides C., et al. "Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonist but not ketosis in man." J. Clin. Endocrinol. Metab. 94(9): 3594-3601 (2009).
  • The CAS number shown above is correct; it is the number originally assigned to this compound by CAS.  Subsequently, CAS granted two other numbers [477740-73-1] and [622402-22-6], but those have been canceled.  As of January 7, 2020, the vast majority of other reagent vendors are showing an incorrect CAS number [622402-22-6], for this compound.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses
1627